Skocz do pozycji: 1.

Tytuł:

Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.

Autorzy:

Tao Y; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Jin S; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Yang D; Department of Hematology, Lu Daopei Hospital, 200025, Shanghai, China.
Pan M; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Ouyang W; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Liu Y; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Wang Y; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Zhang W; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China. .
Mi J; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China. .

Pokaż więcej

Źródło:

BMC cancer [BMC Cancer] 2024 Apr 02; Vol. 24 (1), pp. 406. Date of Electronic Publication: 2024 Apr 02.

Typ publikacji:

Journal Article

MeSH Terms:

Multiple Myeloma*/genetics
Multiple Myeloma*/therapy
Multiple Myeloma*/diagnosis
Hematopoietic Stem Cell Transplantation*
Humans ; Treatment Outcome ; Transplantation, Autologous ; Stem Cell Transplantation ; Chromosome Aberrations ; Neoplasm, Residual/diagnosis

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 2.

Tytuł:

Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission.

Autorzy:

Jia X; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Liao N; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Yu S; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Li H; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Liu H; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Zhang H; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Xu J; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Yao Y; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
He H; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Yu G; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Liu Q; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Zhang Y; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Shi P; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.

Pokaż więcej

Źródło:

Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (4), pp. e7074.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/therapy
Leukemia, Myeloid, Acute*/metabolism
Adult ; Humans ; Transplantation, Homologous ; Stem Cell Transplantation ; Recurrence ; Pathologic Complete Response ; Neoplasm, Residual ; Retrospective Studies ; Prognosis

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 3.

Tytuł:

Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.

Autorzy:

Guman T
Sykora J

Pokaż więcej

Źródło:

Bratislavske lekarske listy [Bratisl Lek Listy] 2024; Vol. 125 (1), pp. 9-11.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/methods
Multiple Myeloma*/genetics
Multiple Myeloma*/therapy
Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chromosome Aberrations ; Disease Progression ; Disease-Free Survival ; Progression-Free Survival ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation, Autologous ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 4.

Tytuł:

Autologous Stem Cell Transplant in Hodgkin's and Non-Hodgkin's Lymphoma, Multiple Myeloma, and AL Amyloidosis.

Autorzy:

Alnasser SM; Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
Alharbi KS; Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
Almutairy AF; Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
Almutairi SM; Unaizah College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia.
Alolayan AM; Unaizah College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia.

Pokaż więcej

Źródło:

Cells [Cells] 2023 Dec 18; Vol. 12 (24). Date of Electronic Publication: 2023 Dec 18.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*/therapy
Immunoglobulin Light-chain Amyloidosis*/therapy
Lymphoma, Non-Hodgkin*/therapy
Humans ; Transplantation, Autologous ; Stem Cell Transplantation

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 5.

Tytuł:

Stem Cell Therapy in Children with Traumatic Brain Injury.

Autorzy:

Lin WY; Department of Pediatrics, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
Wu KH; Department of Pediatrics, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.; School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
Chen CY; Department of Emergency Medicine, Tung's Taichung MetroHarbor Hospital, Taichung 433, Taiwan.; Department of Nursing, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli 79-9, Taiwan.
Guo BC; Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Chang YJ; Laboratory of Epidemiology and Biostastics, Changhua Christian Hospital, Changhua 500, Taiwan.
Lee TA; Department of Emergency Medicine, Chang Bing Show Chwan Memorial Hospital, Changhua 505, Taiwan.
Lin MJ; Division of Cardiology, Department of Medicine, Taichung Tzu Chi Hospital, The Buddhist Tzu Chi Medical Foundation, Taichung 427413, Taiwan.; Department of Medicine, College of Medicine, Tzu Chi University, Hualien 970, Taiwan.
Wu HP; College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.; Department of Pediatrics, Chiayi Chang Gung Memorial Hospital, Chiayi 613, Taiwan.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2023 Sep 28; Vol. 24 (19). Date of Electronic Publication: 2023 Sep 28.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Brain Injuries, Traumatic*/therapy
Mesenchymal Stem Cell Transplantation*
Humans ; Child ; Stem Cell Transplantation ; Cognition

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 6.

Tytuł:

Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma.

Autorzy:

Zhang C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Deng J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Xie Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Mi L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Liu W; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Wang X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Zhao L; Department of Lymphoma, Peking University International Hospital, Beijing, China.
Song Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Zhu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.

Pokaż więcej

Źródło:

Cancer medicine [Cancer Med] 2023 May; Vol. 12 (9), pp. 10351-10362. Date of Electronic Publication: 2023 Apr 20.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Hematopoietic Stem Cell Transplantation*
Hodgkin Disease*/drug therapy
Humans ; East Asian People ; Neoplasm Recurrence, Local ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation, Autologous

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 7.

Tytuł:

Exercise prehabilitation for people with myeloma undergoing autologous stem cell transplantation: results from PERCEPT pilot randomised controlled trial.

Autorzy:

McCourt O; Therapies & Rehabilitation, University College London Hospitals NHS Foundation Trust, London, UK.; Department of Haematology, UCL Cancer Institute, University College London, London, UK.
Fisher A; UCL Department of Behavioural Science and Health, University College London, London, UK.
Ramdharry G; Queens Square Centre for Neuromuscular Diseases, National Hospital for Neurology & Neurosurgery, UCLH NHS Trust/UCL Institute of Neurology, University College London, London, UK.
Land J; Department of Haematology, UCL Cancer Institute, University College London, London, UK.; UCL Department of Behavioural Science and Health, University College London, London, UK.
Roberts AL; UCL Department of Behavioural Science and Health, University College London, London, UK.
Rabin N; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Yong K; Department of Haematology, UCL Cancer Institute, University College London, London, UK.

Pokaż więcej

Źródło:

Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2023 Jul; Vol. 62 (7), pp. 696-705. Date of Electronic Publication: 2023 Feb 15.

Typ publikacji:

Randomized Controlled Trial; Journal Article

MeSH Terms:

Multiple Myeloma*/therapy
Hematopoietic Stem Cell Transplantation*/methods
COVID-19*/epidemiology
Humans ; Quality of Life ; Preoperative Exercise ; Hand Strength ; Pandemics ; Pilot Projects ; Transplantation, Autologous ; Stem Cell Transplantation ; Exercise ; Fatigue/etiology ; Exercise Therapy/methods

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 8.

Tytuł:

Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis.

Autorzy:

Lin CM; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Otolaryngology, National Taiwan University Hospital, Yun-Lin Branch, Yun-Lin, Taiwan.
Chang LC; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Division of Hospital Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Shau WY; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chen CL; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Yao CY; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Zhongshan S. Rd., Zhongzheng Dist., Taipei City, 100225, Taiwan.
Tien FM; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. .; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Zhongshan S. Rd., Zhongzheng Dist., Taipei City, 100225, Taiwan. .

Pokaż więcej

Źródło:

BMC cancer [BMC Cancer] 2023 May 16; Vol. 23 (1), pp. 446. Date of Electronic Publication: 2023 May 16.

Typ publikacji:

Meta-Analysis; Systematic Review; Journal Article

MeSH Terms:

Multiple Myeloma*/therapy
Multiple Myeloma*/drug therapy
Hematopoietic Stem Cell Transplantation*
Male ; Humans ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Transplantation, Autologous ; Disease-Free Survival ; Stem Cell Transplantation

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 9.

Tytuł:

Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era.

Autorzy:

Zhou H; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Jian Y; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Du J; Department of Hematology, The Myeloma & Lymphoma Center, The Second Military Medical University, Shanghai, China.
Liu J; Department of Hematology, The First Affiliated Hospital to Sun Yat-sen University, Guangdong, Guangzhou, China.
Zhang Z; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Yang G; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Wang G; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Tian Y; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Li Y; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Wu Y; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Chen W; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Fu W; Department of Hematology, The Myeloma & Lymphoma Center, The Second Military Medical University, Shanghai, China.; Department of Hematology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Li J; Department of Hematology, The First Affiliated Hospital to Sun Yat-sen University, Guangdong, Guangzhou, China.
Gao W; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.

Pokaż więcej

Źródło:

Cancer medicine [Cancer Med] 2023 Apr; Vol. 12 (8), pp. 9085-9096. Date of Electronic Publication: 2023 Apr 06.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Multiple Myeloma*/drug therapy
Hematopoietic Stem Cell Transplantation*
Humans ; Prognosis ; Nomograms ; Retrospective Studies ; Transplantation, Autologous ; Stem Cell Transplantation ; Recurrence

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 10.

Tytuł:

Tandem autologous stem cell transplantation in elderly patients with myeloma: A multicenter retrospective analysis.

Autorzy:

Suzuki K; Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, Japan.; Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Kashiwa, Japan.
Mizuno S; Division of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan.
Shimazu Y; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Fuchida SI; Department of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Hagiwara S; Division of Hematology, Tsukuba University Hospital Mito Clinical Education and Training Center, Tsukuba, Japan.
Itagaki M; Department of Hematology, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Nishiwaki K; Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, Japan.; Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Kashiwa, Japan.
Hangaishi A; Department of Hematology, National Center for Global Health and Medicine, Tokyo, Japan.
Karasuno T; Division of Hematology, Rinku General Medical Center, Izumisano, Japan.
Kikuchi T; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Shimizu M; Department of Hematology and Oncology, Hitachi, Ltd. Hitachi General Hospital, Hitachi, Japan.
Nishikawa A; Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Kobayashi T; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Sunami K; Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Hiramoto N; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Uchiyama H; Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Maruyama Y; Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Kanda Y; Division of Hematology, Jichi Medical University, Shimotsuke, Japan.
Ichinohe T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Aichi, Japan.; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Aichi, Japan.
Yano S; Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Kashiwa, Japan.
Kawamura K; Division of Clinical Laboratory Medicine, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Tottori, Japan.

Pokaż więcej

Corporate Authors:

Working Group of the Japan Society
for Transplantation and Cellular Therapy

Źródło:

European journal of haematology [Eur J Haematol] 2023 Apr; Vol. 110 (4), pp. 444-454. Date of Electronic Publication: 2023 Jan 17.

Typ publikacji:

Multicenter Study; Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*
Humans ; Aged ; Retrospective Studies ; Transplantation, Autologous ; Stem Cell Transplantation

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 11.

Tytuł:

Successful Allogeneic Stem Cell Transplantation with Ruxolitinib Maintenance Therapy for CSF3R T618I Mutant Chronic Neutrophilic Leukemia

Autorzy:

Ye P; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, Zhejiang, China
Lin Q; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, Zhejiang, China
Jin M; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, Zhejiang, China
Gu X; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, Zhejiang, China
Lu Y; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, Zhejiang, China

Pokaż więcej

Źródło:

Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2023 Feb 28; Vol. 40 (1), pp. 73-74. Date of Electronic Publication: 2022 Dec 13.

Typ publikacji:

Journal Article

MeSH Terms:

Leukemia, Neutrophilic, Chronic*/genetics
Leukemia, Neutrophilic, Chronic*/therapy
Hematopoietic Stem Cell Transplantation*
Humans ; Nitriles ; Stem Cell Transplantation ; Mutation ; Receptors, Colony-Stimulating Factor/genetics

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 12.

Tytuł:

Prehabilitation to improve outcomes afteR Autologous sTem cEll transplantation (PIRATE): A pilot randomised controlled trial protocol.

Autorzy:

Dennett AM; School of Allied Health, Human Services and Sport, La Trobe University, Bundoora, Australia.; Allied Health Clinical Research Office, Eastern Health, Box Hill, Australia.
Porter J; Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Burwood, Australia.
Ting SB; Department of Clinical Haematology, Eastern Health, Box Hill, Australia.; Eastern Health Clinical School, Monash University, Box Hill, Australia.
Taylor NF; School of Allied Health, Human Services and Sport, La Trobe University, Bundoora, Australia.; Allied Health Clinical Research Office, Eastern Health, Box Hill, Australia.

Pokaż więcej

Źródło:

PloS one [PLoS One] 2023 Apr 27; Vol. 18 (4), pp. e0277760. Date of Electronic Publication: 2023 Apr 27 (Print Publication: 2023).

Typ publikacji:

Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Hematopoietic Stem Cell Transplantation*
Humans ; Pilot Projects ; Quality of Life ; Preoperative Exercise ; Transplantation, Autologous ; Australia ; Stem Cell Transplantation ; Randomized Controlled Trials as Topic

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 13.

Tytuł:

Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study.

Autorzy:

Jung J; Center for Hematologic Malignancies, National Cancer Center, Goyang, Korea.
Kim K; Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jung SH; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Yoon SS; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Lee JH; Division of Hematology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Kim JS; Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Shin HJ; Department of Hematology-Oncology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
Bang SM; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Sohn SK; Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Suh C; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Yoon DH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kong SY; Targeted Therapy Branch, Research Institute, National Cancer Center, Goyang, Korea.; Department of Laboratory Medicine, Hospital, National Cancer Center, Goyang, Korea.; Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea.
Min CK; Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Eom HS; Center for Hematologic Malignancies, National Cancer Center, Goyang, Korea.

Pokaż więcej

Corporate Authors:

Korean Multiple Myeloma Working Party; Center for Hematologic Malignancies, National Cancer Center, Goyang, Korea.

Źródło:

Cancer research and treatment [Cancer Res Treat] 2023 Apr; Vol. 55 (2), pp. 693-703.

Typ publikacji:

Clinical Trial, Phase II; Journal Article

MeSH Terms:

Multiple Myeloma*/drug therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans ; Bortezomib/adverse effects ; Dexamethasone/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Transplantation, Autologous ; Cyclophosphamide/adverse effects ; Stem Cell Transplantation/methods ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 14.

Tytuł:

Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.

Autorzy:

Kaloyannidis P; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Zayer M; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Darweesh M; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Batran M; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Garni A; Department of Pathology & Laboratory Medicine, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Naim A; Medical Imaging Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Hashmi H; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Kanfar S; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Pokaż więcej

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 742-745. Date of Electronic Publication: 2023 Jan 11.

Typ publikacji:

Journal Article

MeSH Terms:

Hodgkin Disease*/drug therapy
Hodgkin Disease*/pathology
Hematopoietic Stem Cell Transplantation*
Immunoconjugates*/therapeutic use
Humans ; Brentuximab Vedotin ; Bendamustine Hydrochloride ; Salvage Therapy ; Neoplasm Recurrence, Local ; Transplantation, Autologous ; Stem Cell Transplantation ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 15.

Tytuł:

Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice.

Autorzy:

Montoro MJ; Department of Hematology, Hospital Universitari Vall d´Hebron, Barcelona, Spain.
Pomares H; ICO-Hospital Duran i Reynals, IDIBELL, L'Hospitalet de Llobregat, Spain.
Coll R; ICO-Hospital Universitari Doctor Josep Trueta, Girona, Spain.
Bernal Del Castillo T; Hospital Universitario Central de Asturias, Oviedo, Spain.
Tormo M; Hospital Clínico Universitario de Valencia e Instituto de Investigación INCLIVA, Valencia, Spain.
Jiménez A; Hospital Universitario Ramón y Cajal, Madrid, Spain.
Brunet S; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Casaño J; Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain.
Oiartzabal I; Hospital Universitario Araba, Vitoria-Gasteiz, Spain.
Díez-Campelo M; Hospital Clínico Universitario de Salamanca, Salamanca, Spain.
Ramos F; Hospital Universitario de León, León, Spain.
Romero R; Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.
Salido-Fiérrez E; Hospital Clínico Universitario Virgen de la Arrixaca-IMIB, Murcia, Spain.
Pedro C; Hospital del Mar, Barcelona, Spain.
Bargay J; Hospital Son Llàtzer, Palma de Mallorca, Spain.
Muñoz-Novas C; Hospital Universitario Infanta Leonor, Madrid, Spain.
López R; Celgene S.L.U., a Bristol-Myers Squibb Company, Madrid, Spain.
Rafel M; Celgene S.L.U., a Bristol-Myers Squibb Company, Madrid, Spain.
Valcárcel D; Department of Hematology, Hospital Universitari Vall d´Hebron, Barcelona, Spain.

Pokaż więcej

Corporate Authors:

ERASME study group

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 679-690. Date of Electronic Publication: 2022 Dec 28.

Typ publikacji:

Observational Study; Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Myelodysplastic Syndromes*/therapy
Myelodysplastic Syndromes*/drug therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Male ; Humans ; Aged ; Female ; Prospective Studies ; Treatment Outcome ; Stem Cell Transplantation

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 16.

Tytuł:

Reduced cardiovascular reserve capacity in long-term allogeneic stem cell transplant survivors.

Autorzy:

Dillon HT; Baker Heart and Diabetes Institute, Melbourne, Australia.; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.
Foulkes S; Baker Heart and Diabetes Institute, Melbourne, Australia.; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.; University of Melbourne, Melbourne, Australia.
Horne-Okano YA; Baker Heart and Diabetes Institute, Melbourne, Australia.
Kliman D; Malignant Haematology and Stem Cell Transplantation Service, Alfred Hospital, Melbourne, Australia.
Dunstan DW; Baker Heart and Diabetes Institute, Melbourne, Australia.; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.
Daly RM; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.
Fraser SF; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.
Avery S; Malignant Haematology and Stem Cell Transplantation Service, Alfred Hospital, Melbourne, Australia.
Kingwell BA; Baker Heart and Diabetes Institute, Melbourne, Australia.; CSL Ltd, Melbourne, Australia.
La Gerche A; Baker Heart and Diabetes Institute, Melbourne, Australia.; University of Melbourne, Melbourne, Australia.; Cardiology Department, St Vincent's Hospital Melbourne, Fitzroy, Australia.
Howden EJ; Baker Heart and Diabetes Institute, Melbourne, Australia. .; University of Melbourne, Melbourne, Australia. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2023 Feb 06; Vol. 13 (1), pp. 2112. Date of Electronic Publication: 2023 Feb 06.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Ventricular Function, Left*
Hematopoietic Stem Cell Transplantation*
Male ; Humans ; Female ; Stroke Volume ; Survivors ; Exercise Test/methods ; Stem Cell Transplantation ; Oxygen Consumption

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 17.

Tytuł:

Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.

Autorzy:

Kumar L; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Sahoo RK; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Kumar S; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Baa AK; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Tansir G; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Pathak N; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Malik PS; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Sharma OD; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Mathew A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Jha A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Gupta R; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Sharma A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Biswas A; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.
Kumar R; Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Thulkar S; Department of Radio-diagnosis, All India Institute of Medical Sciences, New Delhi, India.
Malik S; Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Dutt A; Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.

Pokaż więcej

Corporate Authors:

for AIIMS Myeloma Group

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2023 Feb; Vol. 64 (2), pp. 378-387. Date of Electronic Publication: 2022 Nov 23.

Typ publikacji:

Journal Article

MeSH Terms:

Multiple Myeloma*/therapy
Multiple Myeloma*/drug therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans ; Melphalan/adverse effects ; Transplantation, Autologous ; Neoplasm Recurrence, Local/drug therapy ; Stem Cell Transplantation ; Treatment Outcome ; Transplantation Conditioning/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 18.

Tytuł:

Allogeneic umbilical cord blood-derived mesenchymal stem cell implantation versus microdrilling combined with high tibial osteotomy for cartilage regeneration.

Autorzy:

Jung SH; Arthroscopy and Joint Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Orthopedic Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 06273, Republic of Korea.
Nam BJ; Arthroscopy and Joint Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Orthopedic Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 06273, Republic of Korea.
Choi CH; Arthroscopy and Joint Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Orthopedic Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim S; Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jung M; Arthroscopy and Joint Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Orthopedic Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Chung K; Arthroscopy and Joint Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Orthopedic Surgery, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea.
Park J; Arthroscopy and Joint Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Orthopedic Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 06273, Republic of Korea.
Jung Y; Department of Orthopedic Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim SH; Arthroscopy and Joint Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. .; Department of Orthopedic Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 06273, Republic of Korea. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Feb 09; Vol. 14 (1), pp. 3333. Date of Electronic Publication: 2024 Feb 09.

Typ publikacji:

Journal Article

MeSH Terms:

Cartilage, Articular*/surgery
Cartilage, Articular*/pathology
Osteoarthritis, Knee*/surgery
Osteoarthritis, Knee*/pathology
Mesenchymal Stem Cells*
Hematopoietic Stem Cell Transplantation*
Mesenchymal Stem Cell Transplantation*
Humans ; Fetal Blood ; Second-Look Surgery ; Osteotomy ; Regeneration

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 19.

Tytuł:

Mucosal microbiotas and their role in stem cell transplantation.

Autorzy:

Ingham AC; Research Group for Genomic Epidemiology, Technical University of Denmark, Kongens Lyngby, Denmark.; Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.
Pamp SJ; Research Group for Genomic Epidemiology, Technical University of Denmark, Kongens Lyngby, Denmark.; Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark.

Pokaż więcej

Źródło:

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica [APMIS] 2022 Dec; Vol. 130 (12), pp. 741-750. Date of Electronic Publication: 2022 Feb 09.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Graft vs Host Disease*/microbiology
Microbiota*
Humans ; Transplantation, Homologous/adverse effects ; Transplantation, Homologous/methods ; Stem Cell Transplantation/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 20.

Tytuł:

Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation.

Autorzy:

Mikulski D; Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.; Department of Hematology, Copernicus Memorial Hospital in Lodz Comprehensive Cancer Center and Traumatology, Lodz, Poland.
Kościelny K; Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
Nowicki M; Department of Hematology, Copernicus Memorial Hospital in Lodz Comprehensive Cancer Center and Traumatology, Lodz, Poland.; Department of Hematology, Medical University of Lodz, Lodz, Poland.
Wawrzyniak E; Department of Hematology, Medical University of Lodz, Lodz, Poland.
Kalwas M; Department of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
Kowalik M; Department of Hematology, Copernicus Memorial Hospital in Lodz Comprehensive Cancer Center and Traumatology, Lodz, Poland.
Pryt M; Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
Sęczkowska E; Department of Anesthesiology and Intensive Medical Therapy, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.
Świątek A; Department of Internal Medicine and Gastroenterology, Clinical Hospital of the Ministry of the Interior and Administration, Warsaw, Poland.
Wierzbowska A; Department of Hematology, Copernicus Memorial Hospital in Lodz Comprehensive Cancer Center and Traumatology, Lodz, Poland.; Department of Hematology, Medical University of Lodz, Lodz, Poland.
Fendler W; Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.; Department of Radiation Oncology, Dana‑Farber Cancer Institute, Boston, MA, USA.

Pokaż więcej

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2023 Jan; Vol. 64 (1), pp. 98-106. Date of Electronic Publication: 2022 Nov 01.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Multiple Myeloma*/therapy
Multiple Myeloma*/drug therapy
Hematopoietic Stem Cell Transplantation*
Humans ; Progression-Free Survival ; Neutrophils ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Transplantation, Autologous ; Lymphocytes ; Stem Cell Transplantation ; Disease-Free Survival ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 21.

Tytuł:

Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation.

Autorzy:

Geng C; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Zhou H; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Wang H; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Li Y; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Leng Y; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Zhang Z; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Jian Y; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Yang G; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China. .
Chen W; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China. .

Pokaż więcej

Źródło:

BMC cancer [BMC Cancer] 2022 Dec 23; Vol. 22 (1), pp. 1349. Date of Electronic Publication: 2022 Dec 23.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/methods
Multiple Myeloma*/diagnosis
Humans ; Aged ; Retrospective Studies ; Transplantation, Autologous ; Prognosis ; Stem Cell Transplantation ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 22.

Tytuł:

Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma.

Autorzy:

Zhang L; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; First Affiliated Hospital of Soochow University, Department of Ultrasound, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Yang H; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Qian C; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Zhou J; The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Department of Hematology, Shenzhen, Guangdong, People's Republic of China.
Zhu Q; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Jiang Y; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Liu S; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Chen X; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Xu T; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Qu C; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Li C; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Jin Z; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Chu J; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, People's Republic of China.
Zhang X; The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Department of Hematology, Shenzhen, Guangdong, People's Republic of China.
Wu D; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, People's Republic of China.
Huang H; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, People's Republic of China.

Pokaż więcej

Źródło:

Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 404-411.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Lymphoma*/therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytarabine/adverse effects ; Etoposide/adverse effects ; Humans ; Melphalan/adverse effects ; Retrospective Studies ; Semustine ; Stem Cell Transplantation ; Transplantation Conditioning/adverse effects ; Transplantation, Autologous

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 23.

Tytuł:

Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation.

Autorzy:

Taranto E; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Redd R; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Jeter E; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
McHugh K; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Crombie JL; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Fisher DC; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Jacobsen E; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Jacobson CA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Kim AI; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
LaCasce AS; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Odejide OO; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Dahi PB; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nieto Y; Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joyce RM; Department of Hematologic Malignancy, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Chen YB; Hematopoietic Cell Therapy and Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
Bonjoc KC; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Chaudhry A; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Herrera AF; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Armand P; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Merryman RW; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.

Pokaż więcej

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (12), pp. 2912-2917. Date of Electronic Publication: 2022 Aug 07.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Hodgkin Disease*/diagnosis
Hodgkin Disease*/therapy
Hodgkin Disease*/pathology
Humans ; Transplantation, Autologous ; Prognosis ; Neoplasm, Residual/diagnosis ; Leukocytes, Mononuclear/pathology ; Neoplasm Recurrence, Local ; Stem Cell Transplantation

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 24.

Tytuł:

Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development.

Autorzy:

Kim DDH; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
Popradi G; Health Centre, McGill University, Montreal, QC H4P 2P5, Canada.
Lepic K; Juravinski Cancer Centre, McMaster University, Hamilton, ON L8V 5C2, Canada.
Paulson K; CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, MB R3E 0V9, Canada.
Allan D; Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Nampoothiri RV; Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Lachance S; Hôpital Maisonneuve-Rosemont, Department of Medicine, University of Montreal, Montreal, QC H3C 3J7, Canada.
Deotare U; London Health Sciences Centre, University of Western Ontario, London, ON N6A 5A5, Canada.
White J; Vancouver General Hospital, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Elemary M; Saskatchewan Cancer Agency, University of Saskatchewan, Saskatchewan, SK S7N 4H4, Canada.
Jamani K; Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 4N2, Canada.
Fraga C; Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS B3H 4R2, Canada.
Lemieux C; CHU de Québec-Université Laval, Université Laval, Québec, QC G1R 2J6, Canada.
Novitzky-Basso I; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
Law AD; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
Kumar R; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
Walker I; Juravinski Cancer Centre, McMaster University, Hamilton, ON L8V 5C2, Canada.
Schultz KR; British Columbia Children's Hospital, University of British Columbia, Vancouver, BC V6H 3N1, Canada.

Pokaż więcej

Corporate Authors:

CTTC Chronic GVHD Guideline Working Group

Źródło:

Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Mar 08; Vol. 31 (3), pp. 1426-1444. Date of Electronic Publication: 2024 Mar 08.

Typ publikacji:

Guideline

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Bronchiolitis Obliterans Syndrome*
Graft vs Host Disease*/drug therapy
Graft vs Host Disease*/etiology
Graft vs Host Disease*/pathology
Adult ; Humans ; Child ; Consensus ; Chronic Disease ; Canada

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 25.

Tytuł:

Gut diversity and the resistome as biomarkers of febrile neutropenia outcome in paediatric oncology patients undergoing hematopoietic stem cell transplantation.

Autorzy:

Sardzikova S; Department of Microbiology and Virology, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia.
Andrijkova K; Department of Microbiology and Virology, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia.
Svec P; Department of Paediatric Haematology and Oncology, Children's Haematology and Oncology Clinic and Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia.
Beke G; Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava, Slovakia.
Klucar L; Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava, Slovakia.
Minarik G; Medirex Group Academy N.P.O., Nitra, Slovakia.
Bielik V; Department of Biological and Medical Science, Faculty of Physical Education and Sport, Comenius University in Bratislava, Bratislava, Slovakia.
Kolenova A; Department of Paediatric Haematology and Oncology, Children's Haematology and Oncology Clinic and Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia.
Soltys K; Department of Microbiology and Virology, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Mar 06; Vol. 14 (1), pp. 5504. Date of Electronic Publication: 2024 Mar 06.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Febrile Neutropenia*
Neoplasms*
Child ; Humans ; Biomarkers ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Escherichia coli

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 26.

Tytuł:

Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis

Autorzy:

Włodarczyk M; Medical University of Silesia, Faculty of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Katowice, Poland
Wieczorkiewicz-Kabut A; Medical University of Silesia, Faculty of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Katowice, Poland
Białas K; Medical University of Silesia, Faculty of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Katowice, Poland
Koclęga A; Medical University of Silesia, Faculty of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Katowice, Poland
Noster I; Medical University of Silesia, Faculty of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Katowice, Poland
Zielińska P; Medical University of Silesia, Faculty of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Katowice, Poland
Helbig G; Medical University of Silesia, Faculty of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Katowice, Poland

Pokaż więcej

Źródło:

Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2024 Mar 01; Vol. 41 (1), pp. 9-15. Date of Electronic Publication: 2024 Feb 13.

Typ publikacji:

Journal Article

MeSH Terms:

Cytomegalovirus Infections*/drug therapy
Cytomegalovirus Infections*/etiology
Cytomegalovirus Infections*/prevention & control
Hematopoietic Stem Cell Transplantation*/adverse effects
Acetates*
Quinazolines*
Adult ; Humans ; Young Adult ; Middle Aged ; Aged ; Cytomegalovirus ; Antiviral Agents/adverse effects ; Retrospective Studies ; Transplantation, Homologous/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 27.

Tytuł:

Robot therapy aids mental health in patients with hematological malignancy during hematopoietic stem cell transplantation in a protective isolation unit.

Autorzy:

Yamada A; Department of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. .
Akahane D; Department of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Takeuchi S; Center for Diversity, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Miyata K; Department of Nursing, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Sato T; Department of Nursing, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Gotoh A; Department of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Feb 27; Vol. 14 (1), pp. 4737. Date of Electronic Publication: 2024 Feb 27.

Typ publikacji:

Randomized Controlled Trial; Journal Article

MeSH Terms:

Hematologic Neoplasms*/therapy
Hematologic Neoplasms*/etiology
Hematopoietic Stem Cell Transplantation*/adverse effects
Robotics*
Humans ; Hydrocortisone ; Mental Health ; Oxytocin

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 28.

Tytuł:

Extracorporeal membrane oxygenation in long-term COVID-19 with severe neutropenia and thrombocytopenia after allogeneic hematopoietic stem cell transplantation: a case report.

Autorzy:

Guo S; Department of Pulmonary and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu, China.; Department of Emergency, the Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu, China.
Zhang L; Department of Emergency, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Gao C; Department of Emergency, the Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu, China.
Lu X; Department of Emergency, the Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu, China.
Song W; Department of Emergency, the Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu, China.
Shen H; Department of Emergency, the Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu, China.
Guo Q; Department of Pulmonary and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu, China. .; Department of Emergency, the Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu, China. .; Department of Emergency and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. .

Pokaż więcej

Źródło:

BMC infectious diseases [BMC Infect Dis] 2024 Feb 20; Vol. 24 (1), pp. 228. Date of Electronic Publication: 2024 Feb 20.

Typ publikacji:

Case Reports; Journal Article

MeSH Terms:

Extracorporeal Membrane Oxygenation*/adverse effects
COVID-19*/therapy
COVID-19*/complications
Respiratory Distress Syndrome*/etiology
Thrombocytopenia*/therapy
Thrombocytopenia*/complications
Neutropenia*/complications
Neutropenia*/therapy
Neoplasms*/complications
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 29.

Tytuł:

Insights into gut microbiomes in stem cell transplantation by comprehensive shotgun long-read sequencing.

Autorzy:

Spohr P; Chair Algorithmic Bioinformatics, Faculty of Mathematics and Natural Sciences, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.; Center for Digital Medicine, Düsseldorf, Germany.
Scharf S; Institute of Medical Microbiology and Hospital Hygiene, Heinrich Heine University Düsseldorf, University Hospital Düsseldorf, Düsseldorf, Germany.
Rommerskirchen A; Institute of Medical Microbiology and Hospital Hygiene, Heinrich Heine University Düsseldorf, University Hospital Düsseldorf, Düsseldorf, Germany.
Henrich B; Institute of Medical Microbiology and Hospital Hygiene, Heinrich Heine University Düsseldorf, University Hospital Düsseldorf, Düsseldorf, Germany.
Jäger P; Department of Hematology, Immunology, and Clinical Immunology, Heinrich Heine University Düsseldorf, University Hospital Düsseldorf, Düsseldorf, Germany.
Klau GW; Chair Algorithmic Bioinformatics, Faculty of Mathematics and Natural Sciences, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. .; Center for Digital Medicine, Düsseldorf, Germany. .
Haas R; Department of Hematology, Immunology, and Clinical Immunology, Heinrich Heine University Düsseldorf, University Hospital Düsseldorf, Düsseldorf, Germany. .
Dilthey A; Institute of Medical Microbiology and Hospital Hygiene, Heinrich Heine University Düsseldorf, University Hospital Düsseldorf, Düsseldorf, Germany. .; Center for Digital Medicine, Düsseldorf, Germany. .
Pfeffer K; Institute of Medical Microbiology and Hospital Hygiene, Heinrich Heine University Düsseldorf, University Hospital Düsseldorf, Düsseldorf, Germany. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Feb 19; Vol. 14 (1), pp. 4068. Date of Electronic Publication: 2024 Feb 19.

Typ publikacji:

Journal Article

MeSH Terms:

Gastrointestinal Microbiome*/genetics
Microbiota*/genetics
Hematopoietic Stem Cell Transplantation*
Humans ; Bacteria/genetics ; Anti-Bacterial Agents ; Fungi/genetics ; DNA, Ribosomal ; Metagenomics/methods

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 30.

Tytuł:

Inventory of current practices regarding hematopoietic stem cell transplantation in metachromatic leukodystrophy in Europe and neighboring countries.

Autorzy:

Schoenmakers DH; Department of Child Neurology, Amsterdam Leukodystrophy Center, Emma's Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Cellular and Molecular Mechanisms, Amsterdam Neuroscience, Amsterdam, The Netherlands.; Medicine for Society, Platform at Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Mochel F; Hôpital La Pitié-Salpêtrière, Assistance-Publique Hôpitaux de Paris, Inserm U1127, Paris, France.
Adang LA; Division of Child Neurology, Children's Hospital of Philadelphia, Philadelphia, USA.
Boelens JJ; Stem Cell Transplantation and Cellular Therapies Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Calbi V; San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), Pediatric Immunohematology Unit and Neurology and Neurophysiology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy.; Pediatric Immunohematology Unit and BMT Program, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy.
Eklund EA; Section for Pediatric Neurology, Skåne University Hospital and Clinical Sciences, Lund, Lund University, 221 84, Lund, Sweden.
Grønborg SW; Center for Inherited Metabolic Diseases, Department of Pediatrics and Adolescent Medicine and Department of Clinical Genetics, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Fumagalli F; San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), Pediatric Immunohematology Unit and Neurology and Neurophysiology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy.
Groeschel S; Department of Paediatric Neurology and Developmental Medicine, University Children's Hospital, Tübingen, Germany.
Lindemans C; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Wilhelmina Children's Hospital, University Medical Center Utrecht, Lundlaan 6, 3584 EA, Utrecht, The Netherlands.
Sevin C; Reference Center for Leukodystrophies, Pediatric Neurology Department, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
Schöls L; Department of Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; German Center of Neurodeenerative Diseases (DZNE), Tübingen, Germany.
Ram D; Department of Paediatric Neurology, Royal Manchester Children's Hospital, Manchester, UK.
Zerem A; Pediatric Neurology Institute, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Graessner H; Institute for Medical Genetics and Applied Genomics, Center for Rare Diseases, University of Tübingen, Tübingen, Germany.
Wolf NI; Department of Child Neurology, Amsterdam Leukodystrophy Center, Emma's Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. .; Cellular and Molecular Mechanisms, Amsterdam Neuroscience, Amsterdam, The Netherlands. .

Pokaż więcej

Źródło:

Orphanet journal of rare diseases [Orphanet J Rare Dis] 2024 Feb 07; Vol. 19 (1), pp. 46. Date of Electronic Publication: 2024 Feb 07.

Typ publikacji:

Journal Article

MeSH Terms:

Leukodystrophy, Metachromatic*/therapy
Hematopoietic Stem Cell Transplantation*/methods
Humans ; Europe ; Magnetic Resonance Imaging ; Consensus

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 31.

Tytuł:

Low-dose fluconazole as a useful and safe prophylactic option in patients receiving allogeneic hematopoietic stem cell transplantation.

Autorzy:

Hirade K; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.
Kusumoto S; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.; Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
Hashimoto H; Clinical Research Management Center of Nagoya City University Hospital, Nagoya, Japan.
Shiraga K; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.
Hagiwara S; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.
Oiwa K; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.
Suzuki T; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.
Kinoshita S; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.
Ri M; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.
Komatsu H; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.
Iida S; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.

Pokaż więcej

Źródło:

Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (3), pp. e6815. Date of Electronic Publication: 2024 Jan 11.

Typ publikacji:

Journal Article

MeSH Terms:

Fluconazole*/adverse effects
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans ; Retrospective Studies ; Antifungal Agents/adverse effects ; Risk Factors

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 32.

Tytuł:

Long-term outcomes for patients with Hodgkin lymphoma at increased risk of progression or relapse.

Autorzy:

Kosydar S; Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Pokaż więcej

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2023 Jan; Vol. 64 (1), pp. 5-17. Date of Electronic Publication: 2022 Oct 10.

Typ publikacji:

Review; Journal Article

MeSH Terms:

Hodgkin Disease*/therapy
Hodgkin Disease*/drug therapy
Hematopoietic Stem Cell Transplantation*
Humans ; Positron Emission Tomography Computed Tomography ; Neoplasm Recurrence, Local ; Stem Cell Transplantation ; Risk Factors ; Transplantation, Autologous

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 33.

Tytuł:

Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myeloma.

Autorzy:

D'Angelo C; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Sudakaran S; Moores Cancer Center, University of California at San Diego, San Diego, CA, USA.
Asimakopoulos F; Wisconsin Institute for Discovery, University of Wisconsin - Madison, Madison, WI, USA.
Hematti P; Department of Medicine, University of Wisconsin Carbone Cancer Center Madison, WI, USA.
El-Gamal D; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Safdar N; Department of Medicine, University of Wisconsin Carbone Cancer Center Madison, WI, USA.
Callander N; Department of Medicine, University of Wisconsin Carbone Cancer Center Madison, WI, USA.

Pokaż więcej

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2023 Jan; Vol. 64 (1), pp. 87-97. Date of Electronic Publication: 2022 Oct 11.

Typ publikacji:

Journal Article; Research Support, N.I.H., Extramural

MeSH Terms:

Multiple Myeloma*/therapy
Multiple Myeloma*/pathology
Hematopoietic Stem Cell Transplantation*/adverse effects
Gastrointestinal Microbiome*
Humans ; Treatment Outcome ; Transplantation, Autologous ; Disease-Free Survival ; Antineoplastic Combined Chemotherapy Protocols ; Stem Cell Transplantation/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 34.

Tytuł:

Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma.

Autorzy:

Gardenswartz A; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Mehta B; Department of Pediatrics, St. Jude Children's Research Hospital, Peoria, IL, USA.
El-Mallawany NK; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
van de Ven C; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Hochberg J; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Flower A; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
Morris E; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Harrison L; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Chu Y; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Basso J; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Gerard P; Department of Radiology, New York Medical College, Valhalla, NY, USA.
Islam H; Department of Pathology, New York Medical College, Valhalla, NY, USA.
Ayello J; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Baxter-Lowe LA; Department of Pathology and Laboratory Medicine, Children's Hospital of Los Angeles, Los Angeles, CA, USA.
Cairo MS; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.; Department of Pathology, New York Medical College, Valhalla, NY, USA.; Department of Medicine, New York Medical College, Valhalla, NY, USA.; Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA.; Department of Cell Biology and Anatomy, Hematology and Stem Cell Transplantation, Valhalla, NY, USA.

Pokaż więcej

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2023 Jan; Vol. 64 (1), pp. 234-237. Date of Electronic Publication: 2022 Oct 19.

Typ publikacji:

Letter; Research Support, Non-U.S. Gov't

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Lymphoma, Non-Hodgkin*/therapy
Humans ; Child ; Young Adult ; Adolescent ; Transplantation, Autologous ; Neoplasm Recurrence, Local ; Immunotherapy/adverse effects ; Transplantation Conditioning ; Stem Cell Transplantation

Raport

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 35.

Tytuł:

Human Umbilical Cord-Based Therapeutics: Stem Cells and Blood Derivatives for Female Reproductive Medicine.

Autorzy:

Rodríguez-Eguren A; IVI Foundation, Health Research Institute La Fe, 46026 Valencia, Spain.; Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT 05610, USA.
Gómez-Álvarez M; IVI Foundation, Health Research Institute La Fe, 46026 Valencia, Spain.
Francés-Herrero E; IVI Foundation, Health Research Institute La Fe, 46026 Valencia, Spain.; Department of Pediatrics, Obstetrics and Gynecology, School of Medicine, University of Valencia, 46010 Valencia, Spain.
Romeu M; Gynecological Service, Consortium General University Hospital of Valencia, 46014 Valencia, Spain.
Ferrero H; IVI Foundation, Health Research Institute La Fe, 46026 Valencia, Spain.
Seli E; Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT 05610, USA.; IVIRMA New Jersey, Basking Ridge, NJ 07920, USA.
Cervelló I; IVI Foundation, Health Research Institute La Fe, 46026 Valencia, Spain.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2022 Dec 14; Vol. 23 (24). Date of Electronic Publication: 2022 Dec 14.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Mesenchymal Stem Cells*/metabolism
Extracellular Vesicles*/metabolism
Mesenchymal Stem Cell Transplantation*
Humans ; Female ; Umbilical Cord ; Stem Cell Transplantation ; Cell Proliferation

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 36.

Tytuł:

The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.

Autorzy:

Yan W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Fan H; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Xu J; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Liu J; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Li L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Du C; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Deng S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Sui W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Hao M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Yi S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Zou D; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Qiu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Xu Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
An G; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

Pokaż więcej

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (12), pp. 2955-2964. Date of Electronic Publication: 2022 Jul 12.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Leukemia, Plasma Cell*/diagnosis
Leukemia, Plasma Cell*/therapy
Hematopoietic Stem Cell Transplantation*
Humans ; Prognosis ; Stem Cell Transplantation ; Chromosome Aberrations

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 37.

Tytuł:

Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study.

Autorzy:

Ferhanoglu B; Division of Hematology, Department of Internal Medicine, Koç University School of Medicine, Istanbul, Turkey.
Kim TM; Department of Internal Medicine, Seoul National University Hospital, Seoul National University Cancer Research Institute, Seoul, South Korea.
Karduss A; Bone Marrow Transplant Program, Instituto de Cancerologia, Clínica las Américas, Medellín, Colombia.
Brittain D; Albert Alberts Stem Cell Transplant Center, Pretoria East Hospital, Pretoria, South Africa.
Tumyan G; Department of Chemotherapy of Hemoblastosis, Blokhin Russian Cancer Research Center, Moscow, Russia.
Al-Mansour M; Adult Medical Oncology, Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, Jeddah, The Kingdom of Saudi Arabia.; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, The Kingdom of Saudi Arabia.
Zerga M; Department of Hematology, Angel Roffo Institute, Buenos Aires, Argentina.
Song Y; Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China.
Rivas-Vera S; Department of Hematology, Instituto Nacional de Cancerologia Mexico, Mexico City, Mexico.
Kwong YL; Bone Marrow Transplant Unit, Queen Mary Hospital, Hong Kong, China.; Hematology Division, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, University of Hong Kong, Hong Kong, China.
Lim ST; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Yeh SP; Division of Hematology and Oncology, Department of Medicine, China Medical University Hospital, Taichung, Taiwan.
Abdillah A; Takeda Pharmaceuticals International AG-Singapore Branch, Singapore, Singapore.
Huang Z; Takeda R&D Data Sciences Institute, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Dalal M; Takeda R&D Data Sciences Institute, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Wan H; Takeda Pharmaceuticals International AG-Singapore Branch, Singapore, Singapore.
Hertzberg M; Department of Clinical Haematology, Prince of Wales Hospital, Sydney, Australia.; University of New South Wales, Sydney, Australia.

Pokaż więcej

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (14), pp. 3317-3330. Date of Electronic Publication: 2022 Oct 06.

Typ publikacji:

Multicenter Study; Journal Article

MeSH Terms:

Hodgkin Disease*/pathology
Hematopoietic Stem Cell Transplantation*/methods
Adult ; Humans ; Retrospective Studies ; Neoplasm Recurrence, Local/pathology ; Cisplatin ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cytarabine ; Stem Cell Transplantation ; Salvage Therapy ; Etoposide

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 38.

Tytuł:

A rapidly expanding cutaneous tumour in the context of a Janus kinase inhibitor agent following allogeneic stem cell transplant.

Autorzy:

Davies A; Department of Dermatology, King's College Hospital, King's College Hospital NHS Foundation Trust, London, UK.
Salisbury J; Department of Histopathology, King's College Hospital, King's College Hospital NHS Foundation Trust, London, UK.
Mehra V; Department of Haematology, King's College Hospital, King's College Hospital NHS Foundation Trust, London, UK.
Papa S; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Basu T; Department of Dermatology, King's College Hospital, King's College Hospital NHS Foundation Trust, London, UK.

Pokaż więcej

Źródło:

Clinical and experimental dermatology [Clin Exp Dermatol] 2022 Nov; Vol. 47 (11), pp. 2059-2064. Date of Electronic Publication: 2022 Aug 25.

Typ publikacji:

Journal Article

MeSH Terms:

Janus Kinase Inhibitors*/therapeutic use
Hematopoietic Stem Cell Transplantation*/adverse effects
Graft vs Host Disease*/drug therapy
Skin Neoplasms*/drug therapy
Humans ; Stem Cell Transplantation

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 39.

Tytuł:

Combination of bone marrow mesenchymal stem cells and moxibustion restores cyclophosphamide-induced premature ovarian insufficiency by improving mitochondrial function and regulating mitophagy.

Autorzy:

Lu G; College of Acupuncture Moxibustion and Tuina, Nanjing University of Chinese Medicine, Nanjing, China.
Li HX; College of Acupuncture Moxibustion and Tuina, Nanjing University of Chinese Medicine, Nanjing, China.
Song ZW; College of Acupuncture Moxibustion and Tuina, Nanjing University of Chinese Medicine, Nanjing, China.
Luo J; College of Acupuncture Moxibustion and Tuina, Nanjing University of Chinese Medicine, Nanjing, China.
Fan YL; College of Acupuncture Moxibustion and Tuina, Nanjing University of Chinese Medicine, Nanjing, China.
Yin YL; College of Acupuncture Moxibustion and Tuina, Nanjing University of Chinese Medicine, Nanjing, China. .
Shen J; College of Acupuncture Moxibustion and Tuina, Nanjing University of Chinese Medicine, Nanjing, China. .
Shen MH; College of Acupuncture Moxibustion and Tuina, Nanjing University of Chinese Medicine, Nanjing, China. .; Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing, China. .

Pokaż więcej

Źródło:

Stem cell research & therapy [Stem Cell Res Ther] 2024 Apr 08; Vol. 15 (1), pp. 102. Date of Electronic Publication: 2024 Apr 08.

Typ publikacji:

Journal Article

MeSH Terms:

Moxibustion*
Mesenchymal Stem Cell Transplantation*
Primary Ovarian Insufficiency*/chemically induced
Primary Ovarian Insufficiency*/therapy
Primary Ovarian Insufficiency*/pathology
Mesenchymal Stem Cells*/metabolism
Humans ; Female ; Rats ; Animals ; Mitophagy ; Reactive Oxygen Species/metabolism ; Carbonyl Cyanide m-Chlorophenyl Hydrazone/adverse effects ; Carbonyl Cyanide m-Chlorophenyl Hydrazone/metabolism ; Cyclophosphamide/adverse effects ; Mitochondria/metabolism ; Ubiquitin-Protein Ligases/metabolism ; Protein Kinases/metabolism ; Hormones/adverse effects ; Hormones/metabolism ; Adenosine Triphosphate/metabolism

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 40.

Tytuł:

A placebo-controlled, crossover trial to investigate the efficacy of tiotropium bromide or placebo added to usual care in stable symptomatic post-hematopoietic stem cell transplantation (HSCT) bronchiolitis obliterans syndrome (BOS).

Autorzy:

Dini N; Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Khoshbin AP; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Aliannejad R; Thoracic Research Center, Department of Internal Medicine, Division of Pulmonary and Critical Care, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Bakhshandeh H; Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Najafizadeh K; Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mehdizadeh M; Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Amini S; Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. .

Pokaż więcej

Źródło:

Trials [Trials] 2024 Apr 06; Vol. 25 (1), pp. 243. Date of Electronic Publication: 2024 Apr 06.

Typ publikacji:

Randomized Controlled Trial; Journal Article

MeSH Terms:

Bronchiolitis Obliterans Syndrome*
Pulmonary Disease, Chronic Obstructive*/diagnosis
Pulmonary Disease, Chronic Obstructive*/drug therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans ; Tiotropium Bromide/adverse effects ; Cross-Over Studies ; Iran ; Bronchodilator Agents/adverse effects ; Double-Blind Method

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 41.

Tytuł:

The mechanisms of MicroRNA 21 in premature ovarian insufficiency mice with mesenchymal stem cells transplantation : The involved molecular and immunological mechanisms.

Autorzy:

Yin N; Reproductive Medicine Center, First Affiliated Hospital of Soochow University, 899 Pinghai Rd, Suzhou, 215000, Jiangsu, China.; International Peace Maternity and Child Health Hospital of China Welfare Institute, Shanghai, 200030, China.
Luo C; Reproductive Medicine Center, First Affiliated Hospital of Soochow University, 899 Pinghai Rd, Suzhou, 215000, Jiangsu, China.
Wei L; Reproductive Medicine Center, First Affiliated Hospital of Soochow University, 899 Pinghai Rd, Suzhou, 215000, Jiangsu, China.
Yang G; Reproductive Medicine Center, First Affiliated Hospital of Soochow University, 899 Pinghai Rd, Suzhou, 215000, Jiangsu, China.
Bo L; Reproductive Medicine Center, First Affiliated Hospital of Soochow University, 899 Pinghai Rd, Suzhou, 215000, Jiangsu, China. .
Mao C; Reproductive Medicine Center, First Affiliated Hospital of Soochow University, 899 Pinghai Rd, Suzhou, 215000, Jiangsu, China. .

Pokaż więcej

Źródło:

Journal of ovarian research [J Ovarian Res] 2024 Apr 04; Vol. 17 (1), pp. 75. Date of Electronic Publication: 2024 Apr 04.

Typ publikacji:

Journal Article

MeSH Terms:

Menopause, Premature*
Mesenchymal Stem Cell Transplantation*
Mesenchymal Stem Cells*/metabolism
MicroRNAs*/genetics
Primary Ovarian Insufficiency*/genetics
Primary Ovarian Insufficiency*/therapy
Primary Ovarian Insufficiency*/chemically induced
Animals ; Female ; Mice ; CD28 Antigens ; Interleukin-10/genetics ; Proto-Oncogene Proteins c-akt

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 42.

Tytuł:

Efficacy and safety of mesenchymal stem cell therapy for ovarian ageing in a mouse model.

Autorzy:

Pei W; Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology and Key Laboratory of Assisted Reproduction, Ministry of Education, Peking University Third Hospital, Beijing, 100191, China.; Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, 100191, China.; State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China.
Fu L; Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology and Key Laboratory of Assisted Reproduction, Ministry of Education, Peking University Third Hospital, Beijing, 100191, China.; Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, 100191, China.; State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China.
Guo W; Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology and Key Laboratory of Assisted Reproduction, Ministry of Education, Peking University Third Hospital, Beijing, 100191, China.; Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, 100191, China.; State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China.
Wang Y; Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology and Key Laboratory of Assisted Reproduction, Ministry of Education, Peking University Third Hospital, Beijing, 100191, China.; Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China.
Fan Y; Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China.
Yang R; Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology and Key Laboratory of Assisted Reproduction, Ministry of Education, Peking University Third Hospital, Beijing, 100191, China.; State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China.
Li R; Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology and Key Laboratory of Assisted Reproduction, Ministry of Education, Peking University Third Hospital, Beijing, 100191, China.; State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China.
Qiao J; Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology and Key Laboratory of Assisted Reproduction, Ministry of Education, Peking University Third Hospital, Beijing, 100191, China. .; State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China. .
Yu Y; Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology and Key Laboratory of Assisted Reproduction, Ministry of Education, Peking University Third Hospital, Beijing, 100191, China. .; Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, 100191, China. .; State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China. .

Pokaż więcej

Źródło:

Stem cell research & therapy [Stem Cell Res Ther] 2024 Apr 03; Vol. 15 (1), pp. 96. Date of Electronic Publication: 2024 Apr 03.

Typ publikacji:

Journal Article

MeSH Terms:

Mesenchymal Stem Cell Transplantation*
Mesenchymal Stem Cells*/metabolism
Mice ; Animals ; Female ; Ovary/metabolism ; Tissue Distribution ; Cell Proliferation ; Disease Models, Animal ; Umbilical Cord

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 43.

Tytuł:

A single-center, open-labeled, randomized, 6-month, parallel-group study to assess the safety and efficacy of allogeneic cultured keratinocyte sheet transplantation for deep second-degree burn wounds: rationale and design of phase I/II clinical trial.

Autorzy:

Farzanbakhsh S; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Shahrbaf MA; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Madani H; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Dahmardei M; Department of Plastic & Reconstructive Surgery, School of Medicine, Stem Cell and Regenerative Medicine Research Center, Shahid Motahari Burns Hospital, Iran University of Medical Sciences, Tehran, Iran.
Sadri B; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Vosough M; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. .

Pokaż więcej

Źródło:

Trials [Trials] 2024 Apr 01; Vol. 25 (1), pp. 226. Date of Electronic Publication: 2024 Apr 01.

Typ publikacji:

Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial

MeSH Terms:

Burns*/diagnosis
Burns*/therapy
Burns*/complications
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans ; Cicatrix/etiology ; Iran ; Keratinocytes ; Skin Transplantation/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 44.

Tytuł:

Human neural stem cells.

Autorzy:

Wang YK; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.; National Stem Cell Resource Center, Chinese Academy of Sciences, Beijing, China.
Yu J; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; National Stem Cell Resource Center, Chinese Academy of Sciences, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Zhang TT; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Ma AJ; Chinese Society for Stem Cell Research, Shanghai, China.; Beijing Technology and Business University, Beijing, China.
Hao J; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.; National Stem Cell Resource Center, Chinese Academy of Sciences, Beijing, China.; Chinese Society for Stem Cell Research, Shanghai, China.
Chen YJ; Institute of Neuroscience, Key Laboratory of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.; Shanghai Center for Brain Science and Brain-Inspired Intelligence Technology, Shanghai, China.
Liu CM; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Liu Y; Institute for Stem Cell and Neural Regeneration, State Key Laboratory of Reproductive Medicine, School of Pharmacy, Nanjing Medical University, Nanjing, China.
Wang CL; Chinese Society for Stem Cell Research, Shanghai, China.; China National Institute of Standardization, Beijing, China.
Zhai PJ; Chinese Society for Stem Cell Research, Shanghai, China.; China National Accreditation Service for Conformity Assessment, Beijing, China.
Xiang AP; Chinese Society for Stem Cell Research, Shanghai, China.; Center for Stem Cell Biology and Tissue Engineering, Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-Sen University, Guangzhou, China.
Li TQ; Chinese Society for Stem Cell Research, Shanghai, China.; State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, Yunnan, China.; Yunnan Key Laboratory of Primate Biomedical Research, Kunming, Yunnan, China.
Tang TS; Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.; State Key Laboratory of Membrane Biology, Institute of Zoology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Beijing, China.
Chen H; Department of Rehabilitation Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Bao XJ; Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wang YL; Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
He WY; China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Fan J; Zhejiang Huode Bioengineering Ltd. Co, Hangzhou, China.
Teng ZQ; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Wang L; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Zhou JX; Chinese Society for Stem Cell Research, Shanghai, China.; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Fu BQ; Chinese Society for Stem Cell Research, Shanghai, China.; National Institute of Metrology, Beijing, China.
Fu YV; University of Chinese Academy of Sciences, Beijing, China.; Chinese Society for Stem Cell Research, Shanghai, China.; State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Feng L; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; National Stem Cell Resource Center, Chinese Academy of Sciences, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Cao JN; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.; Chinese Society for Stem Cell Research, Shanghai, China.
Liang LM; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; National Stem Cell Resource Center, Chinese Academy of Sciences, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.; Chinese Society for Stem Cell Research, Shanghai, China.
Wang L; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.; National Stem Cell Resource Center, Chinese Academy of Sciences, Beijing, China.; Chinese Society for Stem Cell Research, Shanghai, China.
Zhou Q; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.; Chinese Society for Stem Cell Research, Shanghai, China.
Zhang Y; Chinese Society for Stem Cell Research, Shanghai, China.; Zephyrm Biotechnologies Co., Ltd., Beijing, China.
Hu BY; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Zhao TB; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.; Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.; Chinese Society for Stem Cell Research, Shanghai, China.

Pokaż więcej

Źródło:

Cell proliferation [Cell Prolif] 2024 Apr; Vol. 57 (4), pp. e13564. Date of Electronic Publication: 2023 Oct 18.

Typ publikacji:

Journal Article

MeSH Terms:

Stem Cell Transplantation*
Neural Stem Cells*
Humans ; Cell Differentiation ; China

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 45.

Tytuł:

The remodeling of ovarian function: targeted delivery strategies for mesenchymal stem cells and their derived extracellular vesicles.

Autorzy:

Song Y; Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.; Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Wu J; Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Liu Y; Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Xu N; Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.; Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Bai H; Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Wang L; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. .; Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. .
Ai J; Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. .
Li K; Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. .; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. .

Pokaż więcej

Źródło:

Stem cell research & therapy [Stem Cell Res Ther] 2024 Mar 27; Vol. 15 (1), pp. 90. Date of Electronic Publication: 2024 Mar 27.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Extracellular Vesicles*/metabolism
Primary Ovarian Insufficiency*/therapy
Primary Ovarian Insufficiency*/metabolism
Mesenchymal Stem Cells*
Mesenchymal Stem Cell Transplantation*
Humans ; Female ; Quality of Life ; Tissue Distribution

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 46.

Tytuł:

Pros and Cons of Cryopreserving Allogeneic Stem Cell Products.

Autorzy:

Valentini CG; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, 00168 Rome, Italy.
Pellegrino C; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, 00168 Rome, Italy.; Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Teofili L; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, 00168 Rome, Italy.; Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.

Pokaż więcej

Źródło:

Cells [Cells] 2024 Mar 21; Vol. 13 (6). Date of Electronic Publication: 2024 Mar 21.

Typ publikacji:

Journal Article; Review

MeSH Terms:

COVID-19*
Hematopoietic Stem Cell Transplantation*
Humans ; Pandemics ; Transplantation, Homologous

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 47.

Tytuł:

Long Non-Coding RNA-Cardiac-Inducing RNA 6 Mediates Repair of Infarcted Hearts by Inducing Mesenchymal Stem Cell Differentiation into Cardiogenic Cells through Cyclin-Dependent Kinase 1.

Autorzy:

Cui X; Department of Physiology and Pathophysiology, College of Medicine, Yanbian University, Yanji 133002, China.
Dong H; Department of Physiology and Pathophysiology, College of Medicine, Yanbian University, Yanji 133002, China.
Luo S; Department of Physiology and Pathophysiology, College of Medicine, Yanbian University, Yanji 133002, China.
Zhuang B; Department of Physiology and Pathophysiology, College of Medicine, Yanbian University, Yanji 133002, China.
Li Y; Department of Physiology and Pathophysiology, College of Medicine, Yanbian University, Yanji 133002, China.
Zhong C; Department of Physiology and Pathophysiology, College of Medicine, Yanbian University, Yanji 133002, China.
Ma Y; Department of Physiology and Pathophysiology, College of Medicine, Yanbian University, Yanji 133002, China.
Hong L; Department of Physiology and Pathophysiology, College of Medicine, Yanbian University, Yanji 133002, China.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2024 Mar 19; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 19.

Typ publikacji:

Journal Article

MeSH Terms:

Mesenchymal Stem Cell Transplantation*
Mesenchymal Stem Cells*/metabolism
Myocardial Infarction*/genetics
Myocardial Infarction*/therapy
Myocardial Infarction*/metabolism
Quinolines*
RNA, Long Noncoding*/genetics
RNA, Long Noncoding*/metabolism
Thiazoles*
Animals ; Mice ; CDC2 Protein Kinase/genetics ; CDC2 Protein Kinase/metabolism ; Cell Differentiation/genetics ; Mice, Inbred C57BL ; Myocytes, Cardiac/metabolism

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 48.

Tytuł:

The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments.

Autorzy:

Chen T; Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.; Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, 510005, China.
Deng J; Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Zhang Y; Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Liu B; Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Liu R; Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Zhu Y; Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.; Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, 510005, China.
Zhou M; Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Lin Y; Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Xia B; Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Lin K; Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Ma X; Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, 510005, China. ma_.; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 511400, China. ma_.
Zhang H; Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China. .; Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, 510005, China. .

Pokaż więcej

Źródło:

Molecular cancer [Mol Cancer] 2024 Mar 11; Vol. 23 (1), pp. 53. Date of Electronic Publication: 2024 Mar 11.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Receptors, Chimeric Antigen*/genetics
Receptors, Chimeric Antigen*/metabolism
Hematopoietic Stem Cell Transplantation*
Humans ; Immunoglobulin Fragments/metabolism ; T-Lymphocytes ; Receptors, Antigen, T-Cell/metabolism ; Immunotherapy, Adoptive/methods

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 49.

Tytuł:

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.

Autorzy:

Liu Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Ping L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Song Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Tang Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Zheng W; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Liu W; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Ying Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Zhang C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Wu M; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Feng F; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Lin N; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Tu M; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Zhu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Xie Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China. .

Pokaż więcej

Źródło:

BMC medicine [BMC Med] 2024 Mar 07; Vol. 22 (1), pp. 107. Date of Electronic Publication: 2024 Mar 07.

Typ publikacji:

Clinical Trial, Phase II; Journal Article

MeSH Terms:

Hodgkin Disease*/drug therapy
Hodgkin Disease*/etiology
Hodgkin Disease*/pathology
Hematopoietic Stem Cell Transplantation*
Antibodies, Monoclonal, Humanized*
Humans ; Gemcitabine ; Oxaliplatin/therapeutic use ; Neoplasm Recurrence, Local/drug therapy ; Transplantation, Autologous ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 50.

Tytuł:

Prediction model for EBV infection following HLA haploidentical matched hematopoietic stem cell transplantation.

Autorzy:

Cao XH; Peking University People's Hospital, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Fan ZY; Peking University People's Hospital, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Chang YJ; Peking University People's Hospital, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Xu LP; Peking University People's Hospital, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Zhang XH; Peking University People's Hospital, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Huang XJ; Peking University People's Hospital, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Zhao XY; Peking University People's Hospital, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. zhao_.

Pokaż więcej

Źródło:

Journal of translational medicine [J Transl Med] 2024 Mar 06; Vol. 22 (1), pp. 244. Date of Electronic Publication: 2024 Mar 06.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Epstein-Barr Virus Infections*
Humans ; Female ; Male ; Antiviral Agents ; CD8-Positive T-Lymphocytes ; Calibration

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły